Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Nov 24;25(4):791–799. doi: 10.1016/j.bbmt.2018.11.012

Figure 2.

Figure 2.

Cumulative incidence of CMV end-organ disease for CONV and CD34-selected HCT at 1 year after HCT.

Two of 88 CONV developed CMV disease at 19 and 44 days after HCT. Thirteen of 230 CD34- selected HCT developed CMV disease at a median 134 days (98–182) after HCT.